Friday, 16 October 2026European Markets

BARBARA BUI And BENETEAU Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - barbara bui (bui.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
barbara bui (bui.pa) €8.00 4.08% 125.51%
beneteau (ben.pa) €10.82 3.72% 22.43%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. barbara bui (bui.pa)

4.08% forward dividend yield and 125.51% return on equity

barbara bui sa engages in the manufacture, marketing, and sale of ready-to-wear clothing and accessories for women in france and internationally. the company offers coats, jackets, tops and shirts, t-shirts, mesh, pants, dresses and skirts, leather products, and tailored cloths; and accessories, such as shoes, bags, scarves, and belts. it offers its products through wholesale distributors, as well as online and offline stores. the company was incorporated in 1982 and is based in paris, france.

earnings per share

as for profitability, barbara bui has a trailing twelve months eps of €1.04.

pe ratio

barbara bui has a trailing twelve months price to earnings ratio of 7.69. meaning, the purchaser of the share is investing €7.69 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 125.51%.

moving average

barbara bui's value is under its 50-day moving average of €8.43 and under its 200-day moving average of €8.35.

volume

today's last reported volume for barbara bui is 10 which is 80% below its average volume of 50.

volatility

barbara bui's last week, last month's, and last quarter's current intraday variation average was a negative 0.63%, a negative 6.59%, and a positive 13.44%.

barbara bui's highest amplitude of average volatility was 0.63% (last week), 6.59% (last month), and 13.44% (last quarter).

more news about barbara bui.

2. beneteau (ben.pa)

3.72% forward dividend yield and 22.43% return on equity

bénéteau s.a. designs, manufactures, and sells boats and leisure homes in france and internationally. it provides boats under the beneteau, jeanneau, lagoon, prestige, four winns, scarab, wellcraft, excess, and delphia brand names; and leisure homes under the irm, o'hara, and coco sweet brand names. the company also offers bandofbaots.com, a community services platform for purchase and sale of new or used boats; lease purchase, credit, and insurance services through sgb finance; and inventory and retail finance solutions. bénéteau s.a. was founded in 1884 and is headquartered in saint gilles croix de vie, france. bénéteau s.a. operates as a subsidiary of beri 21 s.a.

earnings per share

as for profitability, beneteau has a trailing twelve months eps of €1.99.

pe ratio

beneteau has a trailing twelve months price to earnings ratio of 5.44. meaning, the purchaser of the share is investing €5.44 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.43%.

more news about beneteau.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com